<DOC>
	<DOCNO>NCT02341391</DOCNO>
	<brief_summary>The primary purpose study evaluate safety TissueGene-C , gene therapy product use allogenic human chondrocytes express Transforming Growth Factor ( TGF ) -Î²1 assess inflammation injection site , incidence severity adverse event , physical examination finding , laboratory test result intra-articular injection TissueGene-C. And Secondary purpose evaluate biological efficacy ( knee pain , range motion , functional test , MRI ) TissueGene-C distribution TissueGene-C outside injection site .</brief_summary>
	<brief_title>Safety Biological Efficacy Study TisssueGene-C Degenerative Arthritis</brief_title>
	<detailed_description>TissueGene-C biological new drug consist normal chondrocyte cell transduce chondrocyte cell express growth factor modify osteoarthritis symptom long term period . During clinical trial Phase 1 , compare three different dose level TisssueGene-C 6 month 12 outpatient degenerative arthritis . The patient randomize three different dose level TisssueGene-C 1:1:1 ratio , monitor record alleviating symptom , sport activity , function knee , presence adverse event .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<criteria>1 . Male female patient 2 . Patients age 45 year Grade IV [ base International Cartilage Repair Society ( ICRS ) evaluation criterion MRI scan result ] degenerative arthritis knee , whose symptom relieve conventional symptomatic treatment 3 . Healthy , major physical examination , hematology , serum chemistry , urine test finding significant medical history 4 . Patients cartilage damage size 26 cm2 ( base ICRS evaluation criterion MRI scan result ) 5 . Voluntarily agree participate study sign informed consent form 1 . Showed clinically significant hematology , serum chemistry , urine test result screen visit 2 . Took antiinflammatory medication ( prescribed overthecounter ) , include natural medicine , within 14 day administration investigational product 3 . Has history drug abuse within one year enrollment , urine test blood alcohol test result positive screening visit 4 . Received injection target knee within two month initiation study 5 . Pregnant breastfeed female 6 . With another joint disease apart degenerative arthritis ( e.g. , systemic rheumatic inflammatory disease associate knee chondrocalcinosis , hemachromatosis , inflammatory arthritis , necrosis trochanter , Paget 's disease adjacent joint femur tibia , ochronosis , hemophilic arthropathy , infectious arthritis , Charcot 's disease knee joint , villonodular synovitis , synovial chondroma ) 7 . With infectious disease , include HIV hepatitis ( HBV/HCV ) 8 . With history follow clinically significant disease : heart disease [ e.g. , myocardial infarction , arrhythmia , serious heart disease , coronary artery bypass graft ( CABG ) ] kidney disease ( e.g. , chronic renal failure , glomerulonephritis ) liver disease ( e.g. , liver cirrhosis , fatty liver , acute chronic liver disease ) endocrine disease ( e.g. , hyperthyroidism , hypothyroidism , thyroiditis , diabetes insipidus , Cushing 's disease ) insulindependent diabetes mellitus medical history current malignant tumor In particular , tumor TissueGeneC may aggravate screen use follow test Leukemia : White Blood Cell level hematology Osteochondroma , Chondromas , Chondroblastoma , Chondromyxoid fibroma , Chondrosarcoma : Alkaline phosphatase level hematology 9 . Participated another clinical trial ( use investigational drug medical device ) within 30 day enrollment study 10 . Showed positive drug test result screen visit 11 . Did agree use contraceptive method ( male female )</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>chondrocyte cell</keyword>
	<keyword>Osteoarthritis</keyword>
	<keyword>gene therapy</keyword>
</DOC>